Rohit Joshi

1.3k total citations
50 papers, 408 citations indexed

About

Rohit Joshi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Rohit Joshi has authored 50 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Rohit Joshi's work include Colorectal Cancer Screening and Detection (9 papers), Global Cancer Incidence and Screening (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). Rohit Joshi is often cited by papers focused on Colorectal Cancer Screening and Detection (9 papers), Global Cancer Incidence and Screening (9 papers) and Colorectal Cancer Treatments and Studies (9 papers). Rohit Joshi collaborates with scholars based in Australia, United States and United Kingdom. Rohit Joshi's co-authors include Christos S. Karapetis, David Roder, Timothy Price, Nimit Singhal, David A. Wattchow, Dorothy Keefe, Kate Powell, Kerri Beckmann, Jacqui Adams and Ashish Aneja and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Rohit Joshi

45 papers receiving 401 citations

Peers

Countries citing papers authored by Rohit Joshi

Since Specialization

Citations

This map shows the geographic impact of Rohit Joshi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rohit Joshi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rohit Joshi more than expected).

Fields of papers citing papers by Rohit Joshi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rohit Joshi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rohit Joshi. The network helps show where Rohit Joshi may publish in the future.

Co-authorship network of co-authors of Rohit Joshi

This figure shows the co-authorship network connecting the top 25 collaborators of Rohit Joshi. A scholar is included among the top collaborators of Rohit Joshi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rohit Joshi. Rohit Joshi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in patients with previously treated, advanced NSCLC: Updated dose escalation results in the phase 1 KisMET-01 study. 2025 ·Journal of Clinical Oncology ·Rebecca S. Heist, Elaine Shum, Esther García Pagès, Malinda Itchins, (unknown), (unknown), George R. Blumenschein, Sarah Benafif, Mariam P. Alexander, Rohit Joshi, Jih‐Hsiang Lee, Nicholas Coupe, (unknown), Brian Fiske, (unknown), (unknown), Thao Phuong Nguyen, Tinghui Wu, Gilles Gallant, Chang Gon Kim	1
2	2O Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW 2024 ·Annals of Oncology ·Sara Lonardi, (unknown), Dirk Arnold, Rocio García‐Carbonero, Myriam Chalabi, (unknown), H.J. Lenz, Lars Henrik Jensen, Rohit Joshi, Jeanine M.L. Roodhart, Takashi Yoshino, (unknown), Steven I. Blum, Jonathan T. Sims, (unknown), Fiona Taylor, Tai‐Tsang Chen, Elena Cela, (unknown), E. Van Cutsem	2
3	Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW. 2024 ·Journal of Clinical Oncology ·Heinz‐Josef Lenz, Sara Lonardi, Elena Élez, Eric Van Cutsem, Lars Henrik Jensen, Jaafar Bennouna, Guillermo Méndez, Michael Schenker, Christelle de la Fouchardière, María Luisa Limón, Takayuki Yoshino, Jin Li, José Luís Zamora Manzano, Giampaolo Tortora, Rocio García‐Carbonero, Rohit Joshi, (unknown), Tian Chen, Lixian Jin, Thierry André	7
4	The Impact of Combined Chemotherapy and Intra-Tumoural Injection of Phosphorus-32 Microparticles on Vascularity in Locally Advanced Pancreatic Carcinoma 2024 ·Cancers ·Amanda Lim, (unknown), (unknown), (unknown), Benjamin Crouch, Rohit Joshi, John‐Edwin Thomson, (unknown), (unknown), (unknown), Edmund Tse, Christopher K. Rayner, Andrew Ruszkiewicz, Nimit Singhal, Dylan Bartholomeusz, Nam Q. Nguyen	3
5	A phase 2 randomized study of magrolimab combination therapy in adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): ELEVATE-TNBC. 2023 ·Journal of Clinical Oncology ·(unknown), Rohit Joshi, Joanne Chiu, Ann Chen, Hao Wang, Jared Odegard, (unknown), Sylvia Adams	1
6	698 Safety and tolerability of magrolimab in combination with taxanes in patients with solid tumors 2023 ·SHILAP Revista de lepidopterología ·(unknown), Joanne Chiu, Ulka N. Vaishampayan, Rohit Joshi, Muhammad Furqan, (unknown), Bruno Fang, William Lawler, (unknown), Wen Xu, (unknown), (unknown), Ann Chen, (unknown), (unknown), Sylvia Adams	0
7	Investigating the breast cancer screening–treatment–mortality pathway of women diagnosed with invasive breast cancer: Results from linked health data 2021 ·European Journal of Cancer Care ·Ming Li, (unknown), Katina D’Onise, Gelareh Farshid, Andrew Holmes, Rohit Joshi, Christos S. Karapetis, Caroline Miller, Ian Olver, Elizabeth Buckley, Amanda Townsend, David J. Walters, David Roder	2
8	Monitoring TNM stage of female breast cancer and survival across the South Australian population, with national and international TNM benchmarking: A population-based cohort study 2020 ·BMJ Open ·Ming Li, David Roder, Katina D’Onise, David J. Walters, Gelareh Farshid, Elizabeth Buckley, Christos S. Karapetis, Rohit Joshi, Timothy Price, Amanda Townsend, Caroline Miller, David C. Currow, Kate Powell, (unknown), Ian Olver	5
9	Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide 2020 ·BMC Cancer ·Nikki McCaffrey, (unknown), Belinda Fazekas, (unknown), Meera Agar, Katherine Clark, Simon Eckermann, Jessica Lee, Rohit Joshi, Peter Allcroft, (unknown), David C. Currow	9
10	Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival 2019 ·BMJ Open ·David Roder, Christos S. Karapetis, Ian Olver, Dorothy Keefe, Robert Padbury, James W. Moore, Rohit Joshi, David A. Wattchow, (unknown), Caroline Miller, Carol A. Holden, Elizabeth Buckley, Kate Powell, (unknown), (unknown), Timothy Price	28
11	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer 2018 ·Clinical Cancer Research ·Amanda Townsend, Niall C. Tebbutt, Christos S. Karapetis, Pamela Cooper, Nimit Singhal, (unknown), (unknown), Rohit Joshi, Jennifer E. Hardingham, Timothy Price	6
12	Use of guideline‐recommended adjuvant therapies and survival outcomes for people with colorectal cancer at tertiary referral hospitals in South Australia 2017 ·Journal of Evaluation in Clinical Practice ·Pamela Adelson, (unknown), Christos S. Karapetis, David A. Wattchow, Rohit Joshi, Timothy Price, Greg Sharplin, David Roder	15
13	A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT) 2016 ·Annals of Oncology ·Amanda Townsend, Niall C. Tebbutt, Christos S. Karapetis, Pamela Cooper, Nimit Singhal, (unknown), (unknown), Rohit Joshi, Timothy Price	1
14	Sociodemographic disparities in survival from colorectal cancer in South Australia: a population-wide data linkage study 2015 ·BMC Health Services Research ·Kerri Beckmann, (unknown), Graeme P. Young, Stephen R. Cole, Rohit Joshi, Jacqui Adams, Nimit Singhal, Christos S. Karapetis, David A. Wattchow, David Roder	48
15	Rapid assessment of quantitative T₁, T₂ and T₂* in lower extremity muscles in response to maximal treadmill exercise 2015 ·NMR in Biomedicine ·Juliet Varghese, Debbie Scandling, Rohit Joshi, Ashish Aneja, Jason Craft, Subha V. Raman, Sanjay Rajagopalan, Orlando P. Simonetti, Georgeta Mihai	43
16	Colorectal Cancer Treatment and Survival: the Experience of Major Public Hospitals in South Australia over three Decades 2015 ·Asian Pacific Journal of Cancer Prevention ·David Roder, Christos S. Karapetis, David A. Wattchow, James Moore, Nimit Singhal, Rohit Joshi, Dorothy Keefe, (unknown), Kate Powell, Marion Eckert, Timothy Price	35
17	Metastatic Colorectal Cancer Treatment and Survival: the Experience of Major Public Hospitals in South Australia Over Three Decades 2015 ·Asian Pacific Journal of Cancer Prevention ·David Roder, Christos S. Karapetis, David A. Wattchow, James Moore, Nimit Singhal, Rohit Joshi, Dorothy Keefe, (unknown), (unknown), Greg Sharplin, Timothy Price	4
18	Guillain–Barre syndrome in colorectal cancer 2012 ·Asia-Pacific Journal of Clinical Oncology ·Sina Vatandoust, Rohit Joshi, Timothy Price	3
19	Inferior Gluteal Vein Varicosities 2009 ·JCR Journal of Clinical Rheumatology ·Hema Choudur, Rohit Joshi, Peter L. Munk	8
20	A phase I study to assess the safety and activity of topical lovastatin (FP252S) for the prevention of chemotherapy-induced alopecia 2007 ·Supportive Care in Cancer ·Rohit Joshi, Ian Olver, Dorothy Keefe, (unknown), Keith Smith	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact